Skip to main content
English

Detail

  1. Home
  2. Forschung
  3. Researcher Profiles
  4. Researcher Profiles
  5. Detail
Roza Badr Eslam
Apl. Prof. Privat Doz. Dr. Roza Badr Eslam, MSc.Consultant Cardiologist; Consultant in field of pulmonary vascular disease; Scientific consultant in functional capacity testing for rare disease; Consultant in healthcare and preventive medicine

Department of Medicine II (Division of Cardiology)
Position: Professor

ORCID: 0000-0002-0360-2360
T +43 1 40400 46140
roza.badreslam@meduniwien.ac.at

Keywords

Coronary Artery Disease; Heart Failure; Hypertension; Platelet Function Tests; Rare Diseases

Research group(s)

  • Cardiovascular Medicine
    Research Area: We are combining evaluation and validation of novel non-invasive measurement techniques with cardiovascular drug profiling, i.e. simultaneous recordings of pharmacodynamic effects in different vascular beds, and in vivo investigations of pathophysiological causes, clinical consequences and treatment possibilities in clinical studies.
    Members:

Research interests

Major Research Interests:

  • Thrombosis research, understanding the platelet activation pathways
  • Anticoagulation, platelet aggregation, platelet aggregation inhibitor, platelet function test
  • Heart Failure / cardiac Amyloidosis
  • Understand the pathophysiology of pulmonary vascular disease
  • Study and identify characteristics of stem cells to apply to clinical disorders

Techniques, methods & infrastructure

  • Functional testing modalities / Assessment of usual daily activity and exercise performance in patients with respiratory as well as cardiac diseases
  • Cardiopulmonary exercise testing (CPET)
  • Sit-to-Stand-Test
  • Six-Minute Walk Test (6MWT)

Selected publications

  1. Eslam, R.B. et al. (2009) ‘Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin’, European Heart Journal, 30(15), pp. 1831–1836. Available at: https://doi.org/10.1093/eurheartj/ehp186.
  2. Badr Eslam, R. et al. (2017) ‘Persistence and proliferation of human mesenchymal stromal cells in the right ventricular myocardium after intracoronary injection in a large animal model of pulmonary hypertension’, Cytotherapy, 19(6), pp. 668–679. Available at: https://doi.org/10.1016/j.jcyt.2017.03.002.
  3. Badr Eslam, R. et al. (2022) ‘Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy’, Circulation: Heart Failure, 15(7). Available at: https://doi.org/10.1161/circheartfailure.121.008381.
  4. Kronberger, C. et al. (2025) ‘One-minute sit-to-stand test cut-offs for risk stratification based on six-minute walk test thresholds in pulmonary hypertension’, European Journal of Preventive Cardiology [Preprint]. Available at: https://doi.org/10.1093/eurjpc/zwaf031.
  5. Ermolaev, N. et al. (2025) ‘Cardiopulmonary Exercise Testing Correlates with Quantitative Left Ventricular [99mTc]-DPD Uptake in Transthyretin Amyloid Cardiomyopathy’, Journal of Clinical Medicine, 14(9), p. 2999. Available at: https://doi.org/10.3390/jcm14092999.